QatarTuberculosis profile
Population  2015 2.2 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–0.011) 0.32 (0.19–0.49)
Mortality (HIV+TB only) <0.01 (0–<0.01) 0 (0–0.02)
Incidence  (includes HIV+TB) 0.76 (0.65–0.87) 34 (29–39)
Incidence (HIV+TB only) <0.01 (0–<0.01) 0.03 (0.02–0.04)
Incidence (MDR/RR-TB)** 0.01 (0–0.024) 0.45 (0–1.1)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.047 (0.039–0.055) 0.12 (0.027–0.21) 0.17 (0.066–0.27)
Males <0.01 (<0.01–0.012) 0.58 (0.45–0.7) 0.59 (0.46–0.72)
Total 0.056 (0.043–0.07) 0.7 (0.64–0.76) 0.76 (0.65–0.87)
TB case notifications, 2015  
Total cases notified  
Total new and relapse  
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status  
          - % pulmonary  
          - % bacteriologically confirmed among pulmonary  
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015  
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.01 (0.01–0.02)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
 
(–)
Estimated % of TB cases with MDR/RR-TB 1.3% (0.16–4.7) 15% (13–18)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: , XDR-TB:
Patients started on treatment **** MDR/RR-TB: , XDR-TB:
Treatment success rate and cohort size Success Cohort
New cases registered in 2014    
Previously treated cases registered in 2014    
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data